

News Release Dated October 4, 2013

Company: tella, Inc.
Representative: Yuichiro Yazaki, President & Representative Director
Stock code: 2191, Tokyo Stock Exchange (JASDAQ)
Contact: Ryohei Yamamoto, Director of the Board
(Tel: +81-3-6272-6477)

tella Signs Joint Research Agreement with Kitasato Institute (Kitasato University Kitasato Institute Hospital)

-Phase I clinical study on DC vaccine therapy using cancer antigens for treating hepatocellular carcinoma -

tella, Inc. (Head office: Chiyoda-ku, Tokyo; President and Representative Director: Yuichiro Yazaki; hereinafter “the Company”) has signed a joint research agreement with the Kitasato Institute (Address: Minato-ku, Tokyo; Chairman of the Board of Trustees: Kiyotaka Fujii). Based on this agreement, a phase I clinical study will begin with Kitasato University Kitasato Institute Hospital (hereinafter “Kitasato Institute Hospital”) for the dendritic cell (DC) vaccine therapy using cancer antigens for treating hepatocellular carcinoma (liver cancer).

The cancer antigens used in this collaborative clinical study are cancer antigens for hepatocellular carcinoma that incorporate the cytoplasmic transduction peptide (CTP) developed by JW CreaGene (Head office: Jungwon-gu, Seongnam-si, Gyeonggi-do, Korea). CTP is a technology for increasing the permeability of cell membranes by linking the membranes with proteins and peptides. The purpose of this collaborative clinical study is to confirm the safety of the DC vaccine therapy when using cancer antigens for hepatocellular carcinoma that are linked to CTP.

This collaborative clinical study will be supervised and performed by Dr. Keiichi Suzuki, chief of surgery at Kitasato Institute Hospital. The Company has technologies, know-how and a variety of basic data concerning the DC vaccine therapy. All of these resources will be provided by the Company for this collaborative clinical study.

The Company and Kitasato Institute Hospital will use this collaborative clinical study to accumulate data based on the scientific evidence for the DC vaccine therapy. The purpose is to evaluate the safety of the treatment.

This matter will have only a negligible effect on results of operations in fiscal 2013.